Out-of-protocol concurrent use of cisplatin and radiation therapy in locally advanced cervical cancer: feasibility and survival

Purpose of investigation: We assessed the feasibility, response rates, and overall survival of patients with locally advanced cervical cancer treated with cisplatin-based chemotherapy during radiation therapy on an out-of-protocol basis. Methods: Sixty-nine consecutive newly diagnosed untreated patients with locally advanced cervical cancer who received chemoradiation between 1999 and 2003 were retrospectively reviewed. Treatment consisted in external beam radiation followed by one 137-cessium intracavitary application. Cisplatin was administered for six weeks during external beam radiation. Results: Treatment was well tolerated, although 52 patients presented some degree of acute adverse toxicity (gastrointestinal 65%, hematological 48%, genitourinary 10%). The 3-year survival rate was 61.8% (95% CI 54.5-69.0), with a mean 41.8 months (95% CI 35.7-48.3). Overall survival after adjusting by FIGO Stage IB2-IIA and IIB-IVA was 73.9% and 50%, respectively (p = 0.1839). Overall survival according to Stages IB2-IIb and III-IVA was 74.8% and 34.9%, respectively (p = 0.0376). Conclusion: In patients with locally advanced cervical cancer, adding a weekly regimen of cisplatin to standard pelvic radiation in an out-of-protocol basis is feasible, effective, and showed no unexpected toxicity.

Locally advanced cervical cancer; Cisplatin; Pelvis radiation therapy.

[1] Benedet J., Maisonneuve P, Severi G., Creasman W., Shephed J.: “Annual report of treatment in gynaecological cancer. Carcinoma of the cervix uteri”. J. Epidemiol. Biostat., 1998, 3, 5.

[2] Moore D.H.: “Cervical cancer”. Obstet. Gynecol., 2006, 107, 1152.

[3] Benedetti-Panici P., Greggi S., Colombo A., Amoroso M., Smaniotto D., Giannarelli D. et al.: “Neoadjuvant chemotherapy and radical surgery versus exclusive radiotherapy in locally advanced squamous cell cervical cancer: results from the Italian multicenter randomized study”. J. Clin. Oncol., 2002, 20, 179.

[4] Sardi J.E., Sananes C., Giaroli A.A., Bermudez A., Ferreira M.H., Soderini A.H.: “Neoadyuvant chemotherapy in cervical carcinoma Stage IIB: a randomized controlled trial”. Int. J. Gynecol. Cancer, 1998, 8, 441.

[5] Leborgne F., Leborgne J.H., Doldán R., Zubizarreta E., Ortega B., Maisonneuve J. et al.: “Induction chemotherapy and radiotherapy of advanced cancer of the cervix: a pilot study and phase III randomized trial”. Int. J. Radiat. Oncol. Biol. Phys., 1997, 37, 343.

[6] Kumar L., Kaushal R., Nandy M., Biswal B.M., Kumar S., Kriplani A. et al.: “Chemotherapy followed by radiotherapy versus radiotherapy alone in locally advanced cervical cancer: a random-ized study”. Gynecol. Oncol., 1994, 54, 307.

[7] Cardenas J., Olguin A., Figueroa F.: “Neoadjuvant chemotherapy (CT) + radiotherapy vs radiotherapy alone in Stage IIIB cervical carcinoma: Preliminary results” (abstract). Proc. Am. Soc. Clin. Oncol., 1992, 11, 232.

[8] Whitney C.W, Sause W., Bundy B.N., Malfetano J.H., Hannigan E. V., Fowler W.C. Jr et al.: “Randomized comparison of fluorouracil plus cisplatin versus hydroxyurea as an adjunct to radia-tion therapy in Stage IIB-IVA carcinoma of the cervix with negative paraaortic lymph nodes: a Gynecologic Oncology Group and Southwest Oncology Group study”. J. Clin. Oncol., 1999, 17, 1339.

[9] Rose P.G., Bundy B.N., Watkins E.B., Thigpen J.T., Deppe G., Maiman M.A. et al.: “Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer”. N. Engl. J. Med., 1999, 340, 1144. Erratum in: N. Engl. J. Med., 1999, 341, 708.

[10] Peters W.A. III, Barrett R.J. II, Stock R.J., Monk B.J., Berek J.S.: “Concurrent chemotherapy and pelvic radiation therapy compared with pelvic radiation therapy alone as adjuvant therapy after radical surgery in high-risk early-stage cancer of the cervix”. J. Clin. Oncol., 2000, 18, 1606.

[11] Morris M., Lu J., Grigsby P.W., Levenback C., Stevens R.: “Pelvic radiation with concurrent chemotherapy compared with pelvic and para-aortic radiation for high-risk cervical cancer”. N. Engl. J. Med., 1999, 340, 1137.

[12] Keys H.M., Stehman F., Muderspach L., Chafe W., Suggs C.L. III: “Cisplatin Radiation and adjuvant hysterectomy compared with radiation and adjuvant hysterectomy for bulky Stage IB cervical carcinoma”. N. Engl. J. Med., 1999, 340, 1154.

[13] Institute N.C.: “NCI issues clinical announcement on cervical cancer: chemotherapy plus radiation imporves survival”. US Department of Health and Human Services. Public Health Service, National Institutes of Health, 1999 (Avalaibel at: http://www.cancer.gov/nescenter/cervicalcancer.): p. Retrieved February 23, 2006.

[14] Argenta P.A., Dusenbery K.E., Chen M.D., Judson P.L., Downs L. S. Jr., Carson L.F.: “Radiation therapy with concomitant and adjunvant cisplatin adn paclitaxel in high-risk cervical cancer: long term follow-up”. Eur. J. Gynaecol. Oncol., 2006, 27, 231.

[15] DiSaia P.J., Creasman W.T.: “Basic principles of chemotherapy”. In: DiSaia P.J., Creasman W.T. (eds.). Clinical Gynecologic Oncology, London, Mosby, 2002, 501.

[16] Cox J.D., Pajak T.F.: “Toxicity criteria of the radiation therapy oncology group (RTOG) and the european organization for research and treatment of cancer (EORTC)”. Int. J. Radiat. Oncol. Biol. Phys., 1995, 31, 1341.

[17] Kaplan E.L., Meier P..: “Nonparametric estimation from incomplete observations”. J. Am. Stat. Assod., 1958, 53, 457.

[18] Stehman F.B., DiSaia P.J., Keys H.M., Larson J.E., Fowler W.C.: “Carcinoma of the cervix treated with radiation therapy:A multivariate analysis of prognostic variables in the Gynecologic Oncology Group”. Cancer, 1991, 67, 2776.

[19] Lanciano R.M., Pajak T.F., Martz K., Hanks G.E.: “The influence of treatment time on outcome for squamous cell cancer of the uterine cervix treated with radiation: a patterns-of-care study”. Int. J. Radiat. Oncol. Biol. Phys., 1993, 25, 391.

[20] Perez C.A., Nene S.M., Camel H.M., Galakatos A., Kao M.S.: “Effect of tumor size on the uterine prognosis of carcinoma of the uterine cervix treated with radiation alone”. Cancer, 1992, 69, 2796.

[21] Perez C.A., Castro-Vita H., Locket M.A.: “Impact of prolongation of overall treatment time and timing of brachyteraphy on outcome of radiation therapy”. Int. J. Radiat. Oncol. Biol. Phys., 1995, 32, 1275.

[22] Fyles A., Barton M., Simm J.: “The effect of treatment duration in the local control of cervix cancer”. Radiother. Oncol., 1992, 5, 273.

[23] Wagenaar H.C., Postema S., Anastasopoulou A., Vader Geest R.J., Reiber J.H.C.: “Tumor diameter and volume asessed by magnetic Resonance Imaging in the prediction of outcome for invasive cervical cancer”. Gynecol. Oncol., 2001, 82, 474.

[24] Mayr N.A., Taoka T., Yuh W.T.C., Denning L.M., Zhen W.K., Paulino A.C. et al.: “Method of timing of tumor volume measurement for outcome prediction in cervical cancer using magnetic resonance imaging”. Int. J. Radiat. Oncol. Biol. Phys., 2002, 52, 14.

[25] Logsdon M.D., Eifel P.J.: “FIGO IIIb squamous cell carcinoma of the cervix an analysis of prognostic factors emphasizing the balance between external beam and intracavitary radiation therapy”. Int. J. Radiat. Oncol. Biol. Phys., 1999, 43, 763.

[26] Kuzuya D.: “Chemoradiotherapy for uterine cancer: current status and perspectives”. Int. J. Clin. Oncol., 2004, 9, 458.

[27] Green J.A., Tierney J.F., Symonds P., Fresco L., Collingwood M., Williams C.J.: “Survival and recurrence after concomitant chemotherapy and radiation therapy for cancer of uterine cervix: a systematic review and meta-analysis”. Lancet, 2001, 358, 781.

[28] Lukka H. Hirte H., Fyles A., Thomas G.: “Concurrent cisplatin-based chemotherapy plus radiotherapy for cervical cancer a meta-analysis”. Clin. Oncol., 2002, 14, 203.

[29] Cetina L., Hinojosa J., Poitevin A., Urib J., López-Graniel C., Cantú D. et al.: “Routine management of locally advanced cervical cancer with concurrent radiation and cisplatin. Five-year results”. BMC Women’s Health, 2006, 6, 3.

[30] Serkies K.: “Concurrent weekly cisplatin and radiotherapy in routine management of cervical cancer: a report on patient compliance and acute toxicity”. Int. J. Radiat. Oncol. Biol. Phys., 2004, 60, 814.

[31] King M., Latief T.N., Hartley A, Fernando I.: “Improved survival after concurrent weekly cisplatin and radiotherapy for cervical carcinoma with assessment of acute and late sideeffects”. Clin. Oncol., 2006, 18, 38.

[32] Pearcey R., Drouin P., Jeffrey J., Johnston D., Lukka H.: “Phase III trial comparing radical radiotherapy with and without cisplatin chemotherapy in patients with advanced squamous cell cancer of the cervix”. J. Clin. Oncol., 2002, 20, 966.

[33] Denton A.S., Matthews S.: “National audit of the management and outcome of carcinoma of the cervix treated with radiotherapy in 1993”. Clin. Oncol., 2000, 12, 347.

[34] Taylor A.: “Chemoradiotherapy for cervix cancer: patterns of relapse and possible mode of action”. Clin. Oncol., 2003, 15, S30.

[35] Tan L.T., Burgess L.: “Acute toxicity of chemoradiotherapy for cervical cancer: The Addenbrooke’s Experience”. Clin. Oncol., 2004, 16, 255.

[36] Perez C.A., Madoc-Jones H.: “Radiation therapy alone in the treatment of carcinoma of uterine cervix: I analysis of tumor recur-rence”. Cancer, 1983, 51, 1393.

[37] Montana G.S.: “Carcinoma of the cervix, Stage III: Results of radiation therapy”. Cancer, 1986, 57, 148.

[38] Hanks G.E.: “Patterns of care outcome studies: Results of the national practice in cancer or the cervix”. Cancer, 1983, 51, 959.

[39] Lomaki R., Hanlon Al, Owen J.B., Hanks G.E.: “Longterm results of treatment of cervical carcinoma in the United States in 1973, 1978 and 1983: Patterns of Care study (PCS)”. Int. J. Radiat. Oncol. Biol. Phys., 1995, 31, 973.

[40] Ikushima H., Furutani S., Yamashita K., Kawanaka T., Kishida Y., Iwamoto S. et al.: “Chemoradiation therapy for cervical cancer: toxicity or concurrent weekly cisplatin”. Radiat. Med., 2006, 24, 115.